OptimizeRx
Market Cap
US$250.5m
Last Updated
2020/08/06 23:32 UTC
Data Sources
Company Financials +
Executive Summary
OptimizeRx Corporation operates as a digital health company that facilitates communication at point-of-care among various stakeholders in healthcare.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with limited growth.
Share Price & News
How has OptimizeRx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OPRX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
16.6%
OPRX
0.4%
US Healthcare Services
3.0%
US Market
1 Year Return
16.0%
OPRX
50.1%
US Healthcare Services
15.8%
US Market
Return vs Industry: OPRX underperformed the US Healthcare Services industry which returned 50% over the past year.
Return vs Market: OPRX matched the US Market which returned 15.4% over the past year.
Shareholder returns
| OPRX | Industry | Market | |
|---|---|---|---|
| 7 Day | 16.6% | 0.4% | 3.0% |
| 30 Day | 17.0% | 8.3% | 6.0% |
| 90 Day | 57.9% | 32.1% | 16.4% |
| 1 Year | 16.0%16.0% | 50.6%50.1% | 18.4%15.8% |
| 3 Year | 359.7%359.7% | 120.6%119.3% | 44.8%35.4% |
| 5 Year | 500.0%500.0% | 150.6%148.3% | 75.7%56.7% |
Price Volatility Vs. Market
How volatile is OptimizeRx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 hours ago | Simply Wall St
Here's What We Learned About The CEO Pay At OptimizeRx Corporation (NASDAQ:OPRX)4 weeks ago | Simply Wall St
If You Had Bought OptimizeRx (NASDAQ:OPRX) Stock Five Years Ago, You Could Pocket A 364% Gain Today1 month ago | Simply Wall St
OptimizeRx (NASDAQ:OPRX) Is In A Good Position To Deliver On Growth PlansValuation
Is OptimizeRx undervalued compared to its fair value and its price relative to the market?
11.9%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OPRX ($17.1) is trading below our estimate of fair value ($19.4)
Significantly Below Fair Value: OPRX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: OPRX is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.
PE vs Market: OPRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OPRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OPRX's PB Ratio (5.8x) is in line with the US Healthcare Services industry average.
Next Steps
Future Growth
How is OptimizeRx forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
118.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OPRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OPRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OPRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OPRX's revenue (25.7% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: OPRX's revenue (25.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OPRX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has OptimizeRx performed over the past 5 years?
-31.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OPRX is currently unprofitable.
Growing Profit Margin: OPRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OPRX is unprofitable, and losses have increased over the past 5 years at a rate of 31.5% per year.
Accelerating Growth: Unable to compare OPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (9.9%).
Return on Equity
High ROE: OPRX has a negative Return on Equity (-15.72%), as it is currently unprofitable.
Next Steps
Financial Health
How is OptimizeRx's financial position?
Financial Position Analysis
Short Term Liabilities: OPRX's short term assets ($27.6M) exceed its short term liabilities ($12.2M).
Long Term Liabilities: OPRX's short term assets ($27.6M) exceed its long term liabilities ($387.7K).
Debt to Equity History and Analysis
Debt Level: OPRX is debt free.
Reducing Debt: OPRX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OPRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OPRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is OptimizeRx current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OPRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OPRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OPRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.6yrs
Average management tenure
CEO
Will Febbo (51 yo)
4.5yrs
Tenure
US$833,990
Compensation
Mr. William J. Febbo, Will, serves as the Independent Director of Modular Medical, Inc. since January 23, 2020. He has been the Chief Executive Officer and Director of OptimizeRx Corp since February 22, 20 ...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD833.99K) is below average for companies of similar size in the US market ($USD1.33M).
Compensation vs Earnings: Will's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.5yrs | US$833.99k | 1.57% $ 3.9m | |
| President | 3yrs | US$462.35k | 0.16% $ 411.8k | |
| Chief Financial Officer | 6.25yrs | US$449.53k | 0.62% $ 1.6m | |
| Chief Commercial Officer | 1.33yrs | US$1.21m | no data | |
| Chief Technology Officer | 0.42yr | no data | no data | |
| Senior Vice President of Pharma | 0.42yr | US$511.63k | 0.97% $ 2.4m | |
| Head of Patient Engagement Solutions | 0.42yr | no data | no data | |
| Senior Vice President of Commercial Operations | 0.83yr | no data | no data | |
| Controller | 1.83yrs | no data | no data | |
| Consultant | 3.58yrs | US$420.99k | no data |
1.6yrs
Average Tenure
53yo
Average Age
Experienced Management: OPRX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.5yrs | US$833.99k | 1.57% $ 3.9m | |
| Independent Director | 2.42yrs | US$145.35k | 0.13% $ 331.8k | |
| Independent Chairman | 3.17yrs | US$155.35k | 0.42% $ 1.1m | |
| Director | 0.083yr | no data | no data | |
| Independent Director | 4.92yrs | US$144.85k | 0.20% $ 512.3k | |
| Head of Medical Advisory Board | 2.42yrs | US$112.91k | no data | |
| Independent Director | 3.58yrs | US$141.85k | 0.20% $ 508.4k |
2.8yrs
Average Tenure
63yo
Average Age
Experienced Board: OPRX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.
Top Shareholders
Company Information
OptimizeRx Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: OptimizeRx Corporation
- Ticker: OPRX
- Exchange: NasdaqCM
- Founded:
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$250.459m
- Shares outstanding: 14.65m
- Website: https://www.optimizerx.com
Number of Employees
Location
- OptimizeRx Corporation
- 400 Water Street
- Suite 200
- Rochester
- Michigan
- 48307
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OPRX | NasdaqCM (Nasdaq Capital Market) | Yes | Common Shares | US | USD | Jun 2005 |
Biography
OptimizeRx Corporation operates as a digital health company that facilitates communication at point-of-care among various stakeholders in healthcare. Its cloud-based solution supports patient adherence to ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/06 23:32 |
| End of Day Share Price | 2020/08/06 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.